ADx scientists have developed several new biomarkers based on its own proprietary antibodies. Two of them are new synaptic biomarkers: SNAP25 and Neuronal Pentraxin 2 (NPTX2).
For SNAP25, a high sensitive platform is needed while a NPTX2 measurment can be done with a simple ELISA.
ADx has also two new monoclonal antibodies that can measure Neurofilament Light in CSF with ELISA.
A NEUROFILAMENT LIGHT IMMUNO-ASSAY TARGETING THE COIL2 REGION AS A BIOMARKER FOR NEURODEGENERATION Poster 713 Wednesday 27 March
Further on, we are pursuing the validation of the measurement of Beta Amyloid 42/40 in blood: A promising test for detecting Amyloid plaque burden in the brain.
Lectures with ADx involvement